These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 22463372)

  • 1. Comparative effectiveness analysis of anticoagulant strategies in a large observational database of percutaneous coronary interventions.
    Wise GR; Schwartz BP; Dittoe N; Safar A; Sherman S; Bowdy B; Hahn HS
    J Interv Cardiol; 2012 Jun; 25(3):278-88. PubMed ID: 22463372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bivalirudin is associated with improved clinical and economic outcomes in heart failure patients undergoing percutaneous coronary intervention: Results from an observational database.
    Pinto DS; Kohli P; Fan W; Kirtane AJ; Kociol RD; Meduri C; Deliargyris EN; Prats J; Reynolds MR; Stone GW; Michael Gibson C
    Catheter Cardiovasc Interv; 2016 Feb; 87(3):363-73. PubMed ID: 26011467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospital.
    Olchanski N; Slawsky KA; Plent S; Kado C; Cyr PL
    Hosp Pract (1995); 2010 Nov; 38(4):138-46. PubMed ID: 21068538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model.
    Borg S; Persson U; Allikmets K; Ericsson K
    Clin Ther; 2006 Nov; 28(11):1947-59. PubMed ID: 17213015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost analysis of bivalirudin versus reference anticoagulants without GP IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention for acute coronary syndrome in routine clinical practice. Pompidou registry.
    Puymirat E; Cohen S; Védrenne G; Caruba T; Sabatier B; Danchin N; Durand E
    Ann Cardiol Angeiol (Paris); 2013 Apr; 62(2):89-94. PubMed ID: 23245394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
    Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
    Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
    Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
    Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
    Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
    J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical and economical evaluation of bivalirudin during percutaneous coronary interventions].
    Caruba T; Chaïb A; Danchin N; Rahal S; Bégué D; Durand E; Prognon P; Lafont A; Sabatier B
    Ann Cardiol Angeiol (Paris); 2010 Apr; 59(2):72-8. PubMed ID: 19962685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
    Pinto DS; Stone GW; Shi C; Dunn ES; Reynolds MR; York M; Walczak J; Berezin RH; Mehran R; McLaurin BT; Cox DA; Ohman EM; Lincoff AM; Cohen DJ;
    J Am Coll Cardiol; 2008 Nov; 52(22):1758-68. PubMed ID: 19022155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
    Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
    Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of antithrombotic treatment on short-term outcomes after percutaneous coronary intervention for left main disease: a pooled analysis from REPLACE-2, ACUITY, and HORIZONS-AMI trials.
    Geisler T; Müller K; Karathanos A; Bocksch W; Gawaz M; Deliargyris E; Bernstein D; Lincoff AM; Mehran R; Dangas G; Stone GW
    EuroIntervention; 2014 May; 10(1):97-104. PubMed ID: 24048204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
    Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
    Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
    Summers KM; Holdford DA; Crouch MA
    Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction.
    Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN
    Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials.
    Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
    Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW;
    Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes.
    Schwenkglenks M; Brazier JE; Szucs TD; Fox KA
    Value Health; 2011 Jan; 14(1):24-33. PubMed ID: 21211483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalirudin therapy is associated with improved clinical and economic outcomes in ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention: results from an observational database.
    Pinto DS; Ogbonnaya A; Sherman SA; Tung P; Normand SL
    Circ Cardiovasc Qual Outcomes; 2012 Jan; 5(1):52-61. PubMed ID: 22235065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.